KiOmed Pharma
La probabilité de faillite calculée de KiOmed Pharma sur 12 mois est de 0,4% (très faible). L'entreprise est active depuis 2012 et le Moniteur belge ne contient aucun signal d'insolvabilité ou d'avertissement. Aucun chiffre de comptes annuels traité n'est disponible ; cette conclusion repose uniquement sur les données du registre et du Moniteur belge.
| Active | 14 ans |
| Sites | 2 |
| Publications | 19 |
Estimation statistique fondée sur des sources publiques, pas un conseil de crédit ni une constatation. Comment calculons-nous cela ?
| Exercice | Type | Dépôt | Référence |
|---|---|---|---|
| 31-12-2025 | volledig | 02-06-2026 | 2026-00132153 |
| 31-12-2024 | volledig | 20-06-2025 | 2025-00163632 |
| 31-12-2023 | volledig | 05-06-2024 | 2024-00115460 |
| 31-12-2022 | volledig | 09-06-2023 | 2023-00116021 |
| 31-12-2021 | volledig | 22-06-2022 | 2022-20081190 |
| 31-12-2020 | volledig | 23-07-2021 | 2021-38500141 |
| 31-12-2019 | volledig | 10-07-2020 | 2020-30900243 |
| 31-12-2018 | volledig | 25-06-2019 | 2019-23300316 |
| 31-12-2017 | volledig | 20-06-2018 | 2018-21700448 |
| 31-12-2016 | volledig | 06-07-2017 | 2017-27900395 |
| NACE primaire | 72109 |
| Forme juridique | SA(014) |
| Date de constitution | 04-06-2012 |
| Status | Actif |
| Code postal | 4041 |
Parcelles liées à cette entreprise via ses adresses BCE (siège, unités d'établissement, succursales), croisées avec le plan parcellaire cadastral. Ceci montre où l'entreprise est active, pas un registre de propriété.
| Parcelle (capakey) | Région | Superficie | Bâtiments | Hauteur / ét. |
|---|---|---|---|---|
| 62042B0366/00B003 | Wallonie | 1,9 ha | - | - |
| 62071B0791/00G004 | Wallonie | 4 437 m² | 1 · 850 m² | 7,2 m · 2 ét. |
Une seule chronologie de tout ce qui est arrivé à cette entreprise, publications, événements d'insolvabilité et de cycle de vie, changements administratifs et comptes annuels déposés.
25-09-2025 2 administrateurs nommés
- Chagral Invest SRL, Bestuurder
- Clarentis Sri, Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Chagral Invest SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Clarentis Sri",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}31-03-2025 Augmentation de capital de 6.046.834,90 € à 14.726.836,31 €
- €8.680.001,41 → €14.726.836,31
- Inbreng in geld · Apport en numéraire
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 14726836.31,
"delta_eur": 6046834.9,
"before_eur": 8680001.41,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KiOmed Pharma"
}
}16-01-2025 Modification des statuts
Détails techniques
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
},
"legal_form_change": {
"new": "",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}13-09-2024 2 administrateurs nommés, 1 démissionnaire
- SPARAXIS S.A., Bestuurder
- Caroline Thielen, Représentant permanent
- EY Réviseurs d'Entreprises SRL, Commissaire
Détails techniques
{
"events": [
{
"kind": "director_out",
"role": "commissaire",
"person": {
"rrn": null,
"name": "EY R\u00E9viseurs d\u0027Entreprises SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "SPARAXIS S.A.",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "repr\u00E9sentant permanent",
"person": {
"rrn": null,
"name": "Caroline Thielen",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma DIVISION LIEGE"
}
}16-08-2023 6 administrateurs nommés
- François Blondel, Président exécutif du conseil d'administration
- Houtaï Choumane, Gedelegeerd bestuurder
- Caroline Thielen, Bestuurder
- Benoît Fellin, Bestuurder
- Marc Nolet, Bestuurder
- Marie Hobe, Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "Pr\u00E9sident ex\u00E9cutif du Conseil d\u0027administration",
"person": {
"rrn": null,
"name": "Fran\u00E7ois Blondel",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur d\u00E9l\u00E9gu\u00E9",
"person": {
"rrn": null,
"name": "Houta\u00EF Choumane",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Caroline Thielen",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Beno\u00EEt Fellin",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Marc Nolet",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Marie Hobe",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}01-06-2023 2 administrateurs nommés
- Chagral Invest Srl, Bestuurder
- Samanda S.A., Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Chagral Invest Srl",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Samanda S.A.",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}03-01-2022 Publication au Moniteur belge, Divers
Détails techniques
{
"stage": null,
"notary": {
"name": "Ariane DENIS",
"firm_city": null,
"firm_name": "Yves Godin \u0026 Ariane Denis, Notaires Associ\u00E9s SRL",
"office_city": "Li\u00E8ge",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2022-01-03",
"filing_date": "2021-12-30",
"act_kind_objet": "CAPITAL, ACTIONS, DIVERS, STATUTS (TRADUCTION,"
},
"decision": {
"body": "bijzondere_algemene_vergadering",
"act_date": "2021-12-22",
"unanimous": null
},
"conversion": {
"effective_date": null,
"jurisdiction_to": "BE",
"legal_form_after": "Soci\u00E9t\u00E9 anonyme",
"jurisdiction_from": "BE",
"legal_form_before": "Soci\u00E9t\u00E9 anonyme"
},
"detected_kind": "other",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0846.318.862",
"name": "KIOMED PHARMA",
"role": "other",
"address": "Rue Haute Claire 4, 4041 Herstal",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"7:180",
"7:187",
"7:188",
"39, \u00A71"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "La soci\u00E9t\u00E9 a divis\u00E9 ses actions existantes par cent, augmentant ainsi le nombre total d\u0027actions de 89.725 \u00E0 8.972.500. Elle a \u00E9galement \u00E9mis 635.000 nouveaux droits de souscription (\u00AB Warrants SOP 2021 \u00BB) pour financer une future augmentation de capital sous condition suspensive.",
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA",
"legal_form": "Soci\u00E9t\u00E9 anonyme"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Ariane DENIS",
"org_rep_person_name": null
},
"summary_narrative": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire de KiOmed Pharma, tenue le 22 d\u00E9cembre 2021, a d\u00E9cid\u00E9 de diviser chaque action existante par cent, portant le capital \u00E0 8.972.500 actions sans valeur nominale. Elle a \u00E9galement \u00E9mis 635.000 droits de souscription (\u00AB Warrants SOP 2021 \u00BB) et a approuv\u00E9 une augmentation de capital conditionnelle \u00E0 l\u0027exercice de ces droits. Les statuts ont \u00E9t\u00E9 modifi\u00E9s pour refl\u00E9ter ces changements, notamment en ajustant le montant du capital \u00E0 5.350.528,90 \u20AC.",
"co_filed_documents": [
"exp\u00E9dition du proc\u00E8s-verbal du 22 d\u00E9cembre 2021",
"les procurations et rapports sp\u00E9ciaux",
"la coordination des statuts"
],
"detected_real_type": "other",
"referenced_correction": null,
"should_reroute_to_category": "capital_shares"
}22-09-2021 2 administrateurs nommés, 1 démissionnaire
- Caroline Thielen, Representant permanent
- EY, Commissaire aux comptes
- Géry Lefebvre, Representant permanent
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "representant permanent",
"person": {
"rrn": null,
"name": "Caroline Thielen",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "representant permanent",
"person": {
"rrn": null,
"name": "G\u00E9ry Lefebvre",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "commissaire aux comptes",
"person": {
"rrn": null,
"name": "EY",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}09-07-2021 Augmentation de capital de 174.000 € à 5.350.528,90 €
- €5.176.528,90 → €5.350.528,90
- Inbreng in geld · Apport en numéraire
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 5350528.9,
"delta_eur": 174000.0,
"before_eur": 5176528.9,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
}
}09-10-2020 1 administrateur nommé, 1 démissionnaire
- Dr Pierre Rigaux, Administrateur indépendant
- Flexximum R&D srl, Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Dr Pierre Rigaux",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Flexximum R\u0026D srl",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}10-03-2020 3 administrateurs nommés, 2 démissionnaires
- Marc Nolet, Bestuurder
- Benoit Fellin, Représentant permanent
- Ernst & Young, Commissaire aux comptes
- Marc Nolet, Bestuurder
- Françoise Leblanc, Représentant permanent
Détails techniques
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Marc Nolet",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Marc Nolet",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "repr\u00E9sentant permanent",
"person": {
"rrn": null,
"name": "Benoit Fellin",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "repr\u00E9sentant permanent",
"person": {
"rrn": null,
"name": "Fran\u00E7oise Leblanc",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "commissaire aux comptes",
"person": {
"rrn": null,
"name": "Ernst \u0026 Young",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}07-08-2019 Augmentation de capital de 985.422,07 € à 5.176.528,90 €
- €4.191.106,83 → €5.176.528,90
- Inbreng in geld · Apport en numéraire
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 5176528.9,
"delta_eur": 985422.0700000003,
"before_eur": 4191106.83,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
}
}28-05-2019 Réduction de capital de 4.313.637,52 € à 4.191.106,83 €
- €8.504.744,35 → €4.191.106,83
Détails techniques
{
"events": [
{
"kind": "capital_decrease",
"after_eur": 4191106.83,
"delta_eur": -4313637.52,
"before_eur": 8504744.35,
"contribution_type": null
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
}
}20-05-2019 Augmentation de capital de 120 € à 8.504.744,35 €
- €8.504.624,35 → €8.504.744,35
- Inbreng in geld · Apport en numéraire
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 8504744.35,
"delta_eur": 120.0,
"before_eur": 8504624.35,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
}
}10-12-2018 Opération sur le capital ou les actions
Détails techniques
{
"events": [],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
}
}25-08-2017 Marie-Laure Moreau nommé commissaire
- Marie-Laure Moreau, Commissaire
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "Marie-Laure Moreau",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOmed Pharma"
}
}06-07-2016 Modification des statuts
Détails techniques
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
},
"legal_form_change": {
"new": "soci\u00E9t\u00E9 anonyme",
"old": "soci\u00E9t\u00E9 anonyme",
"changed": false
}
}30-05-2016 1 administrateur nommé, 1 démissionnaire
- INNODE SA, Bestuurder
- François BLONDEL, Bestuurder
Détails techniques
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Fran\u00E7ois BLONDEL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "INNODE SA",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOmed Pharma"
}
}18-12-2015 3 administrateurs nommés
- KiOmed Pharma, Commis
- S.C.R.L. ERNST & YOUNG REVISEURS D'ENTREPRISE, Auditor
- Monsieur Philippe Pire, Auditor
Détails techniques
{
"events": [
{
"kind": "director_in",
"role": "commis",
"person": {
"rrn": null,
"name": "KiOmed Pharma",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "auditor",
"person": {
"rrn": null,
"name": "S.C.R.L. ERNST \u0026 YOUNG REVISEURS D\u0027ENTREPRISE",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "auditor",
"person": {
"rrn": null,
"name": "Monsieur Philippe Pire",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "SYNOLYNE PHARMA"
}
}Générez une note structurée et factuelle à partir de tous les signaux de ce dossier : risque, santé financière, structure de propriété, mandats et comparaison sectorielle.
| Dénomination légaleFR | KiOmed Pharma |